GLI2 and pachyonychia congenita: Here, we provide evidence for a novel mechanism in which the transcription factor GLI2 acts as a downstream effector of transforming growth factor β1 (TGFβ1) signaling in CAFs to drive therapeutic resistance in PC cells.